セフタジジム
WordNet
- a parenteral cephalosporin (trade names Fortaz and Tazicef) used to treat moderate infections (同)Fortaz, Tazicef
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2013/02/13 20:42:00」(JST)
[Wiki en表示]
Ceftazidime
|
Systematic (IUPAC) name |
(6R,7R,Z)-7-(2-(2-aminothiazol-4-yl)-
2-(2-carboxypropan-2-yloxyimino)acetamido)-8-oxo-
3-(pyridinium-1-ylmethyl)-5-thia-1-aza-bicyclo[4.2.0]
oct-2-ene-2-carboxylate |
Clinical data |
Trade names |
Fortaz, Tazicef |
AHFS/Drugs.com |
monograph |
MedlinePlus |
a686007 |
Pregnancy cat. |
B1 (AU) B (US) |
Legal status |
Prescription Only (S4) (AU) |
Routes |
Intravenous, intramuscular |
Pharmacokinetic data |
Bioavailability |
91% (IM) |
Metabolism |
negligible |
Half-life |
1.6–2 hours |
Excretion |
90–96% renal |
Identifiers |
CAS number |
72558-82-8 |
ATC code |
J01DD02 |
PubChem |
CID 5481173 |
DrugBank |
DB00438 |
ChemSpider |
4587145 Y |
UNII |
DZR1ENT301 Y |
ChEBI |
CHEBI:3508 Y |
ChEMBL |
CHEMBL201 Y |
Chemical data |
Formula |
C22H22N6O7S2 |
Mol. mass |
546.58 g/mol |
SMILES
- O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=NOC(C(=O)O)(C)C)c3nc(sc3)N)C[n+]4ccccc4)C([O-])=O
|
InChI
-
InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1 Y
Key:ORFOPKXBNMVMKC-DWVKKRMSSA-N Y
|
Y (what is this?) (verify)
|
Ceftazidime (INN) (pron.: /sɛfˈtæzɨdiːm/) is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram-positive and Gram-negative bacteria. Unlike most third-generation agents, it is active against Pseudomonas aeruginosa, however it has weaker activity against Gram-positive microorganisms and is not used for such infections. Ceftazidime pentahydrate is marketed under various trade names including Cefzim (Pharco B International), Fortum (GSK), and Fortaz.
Clinical use
Main article: Cephalosporin
Ceftazidime is usually reserved for the treatment of infections caused by Pseudomonas aeruginosa. It is also used in the empirical therapy of febrile neutropenia, in combination with other antibiotics. It is usually given IV or IM every 8–12 hours (2 - 3 times a day), with dosage varying by the indication, infection severity, and/or renal function of the recipient.
Ceftazidine is first line treatment for the rare tropical infection, melioidosis.[1]
Chemistry
In addition to the syn-configuration of the imino side chain, compared to other third-generation cephalosporins, the more complex moiety (containing two methyl and a carboxylic acid group) confers extra stability to β-lactamase enzymes produced by many Gram-negative bacteria. The extra stability to β-lactamases increases the activity of ceftazidime against otherwise resistant Gram-negative organisms including Pseudomonas aeruginosa. The charged pyridinum moiety increases water-solubility.
References
- ^ White NJ (2003). "Melioidosis". Lancet 361 (9370): 1715–722. doi:10.1016/S0140-6736(03)13374-0. PMID 12767750.
Antibacterials: cell envelope antibiotics (J01C-J01D)
|
|
Intracellular |
- inhibit peptidoglycan subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
|
|
Glycopeptide |
- inhibit PG chain elongation: Vancomycin# (Oritavancin
- Telavancin)
- Teicoplanin (Dalbavancin)
- Ramoplanin
|
|
β-lactams/
(inhibit PBP
cross-links) |
Penicillins
(penams)
|
Extended sp.
|
- aminopenicillins: Amoxicillin#
- Ampicillin# (Pivampicillin
- Hetacillin
- Bacampicillin
- Metampicillin
- Talampicillin)
- Epicillin
- carboxypenicillins: Carbenicillin (Carindacillin)
- Ticarcillin
- Temocillin
- ureidopenicillins: Azlocillin
- Piperacillin
- Mezlocillin
- other: Mecillinam (Pivmecillinam)
- Sulbenicillin
|
|
Narrow sp.
|
β-lactamase sensitive
|
- Benzylpenicillin (G)#: Clometocillin
- Benzathine benzylpenicillin#
- Procaine benzylpenicillin#
- Azidocillin
- Penamecillin
- Phenoxymethylpenicillin (V)#: Propicillin
- Benzathine phenoxymethylpenicillin
- Pheneticillin
|
|
β-lactamase resistant
|
- Cloxacillin# (Dicloxacillin
- Flucloxacillin)
- Oxacillin
- Meticillin
- Nafcillin
|
|
|
|
Penems
|
|
|
Carbapenems
|
- Biapenem
- Ertapenem
- antipseudomonal (Doripenem
- Imipenem
- Meropenem)
- Panipenem
|
|
Cephalosporins/Cephamycins
(cephems)
|
1st (PEcK)
|
- Cefazolin#
- Cefacetrile
- Cefadroxil
- Cefalexin
- Cefaloglycin
- Cefalonium
- Cefaloridine
- Cefalotin
- Cefapirin
- Cefatrizine
- Cefazedone
- Cefazaflur
- Cefradine
- Cefroxadine
- Ceftezole
|
|
2nd (HEN)
|
- Cefaclor
- Cefamandole
- Cefminox
- Cefonicid
- Ceforanide
- Cefotiam
- Cefprozil
- Cefbuperazone
- Cefuroxime
- Cefuzonam
- cephamycin (Cefoxitin
- Cefotetan
- Cefmetazole)
- carbacephem (Loracarbef)
|
|
3rd
|
- Cefixime#
- Ceftriaxone#
- antipseudomonal (Ceftazidime#
- Cefoperazone)
- Cefcapene
- Cefdaloxime
- Cefdinir
- Cefditoren
- Cefetamet
- Cefmenoxime
- Cefodizime
- Cefotaxime
- Cefpimizole
- Cefpiramide
- Cefpodoxime
- Cefsulodin
- Cefteram
- Ceftibuten
- Ceftiolene
- Ceftizoxime
- oxacephem (Flomoxef
- Latamoxef ‡)
|
|
4th (antips-)
|
- Cefepime
- Cefozopran
- Cefpirome
- Cefquinome
|
|
5th
|
- Ceftobiprole
- Ceftaroline fosamil
|
|
Veterinary
|
- Ceftiofur
- Cefquinome
- Cefovecin
|
|
|
Monobactams
|
- Aztreonam
- Tigemonam
- Carumonam
- Nocardicin A
|
|
β-lactamase inh.
|
- penam (Sulbactam
- Tazobactam)
- clavam (Clavulanic acid)
|
|
Combinations
|
- Amoxicillin/clavulanic acid#
- Imipenem/cilastatin#
- Ampicillin/flucloxacillin
- Ampicillin/sulbactam (Sultamicillin)
- Piperacillin/tazobactam
|
|
|
Other |
- polymyxins/detergent (Colistin
- Polymyxin B)
- depolarizing (Daptomycin)
- hydrolyze NAM-NAG (Lysozyme)
- Gramicidin
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
|
gr+f/gr+a (t)/gr-p (c)/gr-o
|
drug (J1p, w, n, m, vacc)
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Multiple-locus variable number of tandem repeats (VNTR) fingerprinting (MLVF) and antibacterial resistance profiles of extended spectrum beta lactamase (ESBL) producing Pseudomonas aeruginosa among burnt patients in Tehran.
- Jabalameli F, Mirsalehian A, Sotoudeh N, Jabalameli L, Aligholi M, Khoramian B, Taherikalani M, Emaneini M.SourceDepartment of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Burns : journal of the International Society for Burn Injuries.Burns.2011 Nov;37(7):1202-7. Epub 2011 Jun 24.
- Extended spectrum β-lactamase (ESBL)-producing trait was present in 48 out of the 112 (42.8%) Pseudomonas aeruginosa isolates collected from burn wound infections during a 12-month period. The presence of oxa-10, per-1, veb-1 and ges genes and the multiple-locus variable number of tandem repeats (V
- PMID 21703769
- Diversity and antibiotic resistance of Aeromonas spp. in drinking and waste water treatment plants.
- Figueira V, Vaz-Moreira I, Silva M, Manaia CM.SourceCBQF/Escola Superior de Biotecnologia, Universidade Catolica Portuguesa, R. Dr. Antonio Bernardino de Almeida, 4200-072 Porto, Portugal.
- Water research.Water Res.2011 Nov 1;45(17):5599-611. Epub 2011 Aug 22.
- The taxonomic diversity and antibiotic resistance phenotypes of aeromonads were examined in samples from drinking and waste water treatment plants (surface, ground and disinfected water in a drinking water treatment plant, and raw and treated waste water) and tap water. Bacteria identification and i
- PMID 21907383
Japanese Journal
- 医療関連感染による伝播が疑われたTEM-132型ESBL産生Klebsiella pneumoniaeについて
- 症例報告 バンコマイシンとセフタジジム使用中に発症した偽膜性腸炎の一例
Related Links
- Ceftazidime [CAZ] セフタジジム, セファロスポリン系(oxime型) 1. 商品名 先発品 モダシン静注用0.5g/モダシン静注用1g 【グラクソ・スミスクライン】 後発品 後発品9件 を表示 セパダシン静注用0.5g/セパダシン静注用1g モシール静注用 ...
- Easy to read patient leaflet for ceftazidime. Includes indications, proper use, special instructions, precautions, and possible side effects. ... If OVERDOSE is suspected: Contact 1-800-222-1222 (the American Association of Poison ...
Related Pictures
★リンクテーブル★
[★]
- 英
- ceftazidime, CAZ
- 商
- Fortaz, Ceptaz, Tazicer, Taxidime。セパダシン、モダケミン、モダシン、モベンゾシン
- 関
- セファロスポリン系抗菌薬
-
-
抗菌スペクトル
効果・効能
- モダシン静注用
適応菌種
- 本剤に感性のブドウ球菌属、レンサ球菌属、肺炎球菌、大腸菌、シトロバクター属、クレブシエラ属、エンテロバクター属、セラチア属、プロテウス属、モルガネラ・モルガニー、プロビデンシア属、インフルエンザ菌、シュードモナス属、緑膿菌、バークホルデリア・セパシア、ステノトロホモナス(ザントモナス)・マルトフィリア、アシネトバクター属、ペプトストレプトコッカス属、バクテロイデス属、プレボテラ属(プレボテラ・ビビアを除く)
適応症
- 敗血症、感染性心内膜炎、外傷・熱傷及び手術創等の二次感染、咽頭・喉頭炎、扁桃炎(扁桃周囲炎、扁桃周囲膿瘍を含む)、急性気管支炎、肺炎、肺膿瘍、膿胸、慢性呼吸器病変の二次感染、膀胱炎、腎盂腎炎、前立腺炎(急性症、慢性症)、腹膜炎、胆嚢炎、胆管炎、肝膿瘍、バルトリン腺炎、子宮内感染、子宮付属器炎、子宮旁結合織炎、化膿性髄膜炎、中耳炎、副鼻腔炎
[★]
- 英
- cephalosporin antibiotics, cephalosporin, cephalosporins
- 同
- セフェム系抗菌薬?、セフェム系抗生物質? cephem antibiotic? cephem antibiotics
- 関
- 抗菌薬、βラクタム系抗菌薬 、第三世代抗生物質
特徴
- グラム陽性菌、グラム陰性菌
構造
副作用
- 過敏症(ペニシリン系抗菌薬と同様であるが、頻度はペニシリン系に比べ低い)
- (1)ジスルフィラム様作用、(2)ビタミンK依存性の凝固因子の産生低下(cefotetanとcefoperazoneに特徴的。共通点はN-methylthiotetrazole(NMTT) side chainを持つこと)。(PPC.612)
セフェム系抗菌薬
[★]
- 同
- 第3世代セフェム、第三世代抗生物質 antibiotics of third generation、第三世代セフェム系抗生物質 cephem antibiotics of third generation、第3世代セファロスポリン
- 関
- セファロスポリン系抗菌薬
特徴
- 第3世代セフェム以上は口腔内嫌気性細菌をカバーできる ・・・ わざわざABPC/SBTを選択しなくて良い。
第三世代セフェム
[★]
- 英
- cefoperazone CPZ
- ラ
- cefoperazonum
- 化
- cefoperazone sodium セフォペラゾンナトリウム
- 商
- CEFOBID。スペルゾン、スルタムジン、スルペゾール、スルペラゾン、セフォセフ、セフォビッド、セフォペラジン、セフォン、セフロニック、ナスパルン、バクフォーゼ、ワイスタール
- 関
- セファロスポリン系抗菌薬
-
-
抗菌スペクトル